Skip to Content

Are you based in North America? If yes, switch to our North American website →

TEL/AML1 (ETV6/RUNX1) Translocation, Dual Fusion

Applications
haematology
Catalogue Numbers
LPH 012 (10 tests)
LPH 012-S (5 tests)

The TEL (or ETV6 - Erythroblastosis Variant Gene 6 translocation, ETS) / AML1 (or RUNX1 - Runt-Related Transcription Factor 1) fusion is brought about by the cytogenetically invisible t(12;21) translocation.

This is the most common rearrangement in childhood B-ALL and has been detected using FISH in around 17% of cases1, compared to a pick-up rate of 0.05% by conventional cytogenetics2. The translocation is associated with a favourable outcome and has been associated with late relapse3. TEL has also been shown to be deleted in some children with ALL with loss of heterozygosity (LOH) of chromosome 12p12-13 and this deletion is often associated with a TEL/AML1 translocation4. Both the TEL and AML1 genes encode transcription factors and TEL has been shown to be required for proper transcription during haematopoiesis within the bone marrow5.

I am grateful for the excellent products I receive from Cytocell at a reasonable price, but more importantly the superb customer support.  The speed in which I receive answers or suggestions makes my life as a director much easier and allows me to focus on patient care.  The quality and consistency of Cytocell’s probes means I can trust the results, and my clients get their results in a timely manner. Dr. Theresa C. Brown, Director, Cytogenetics Laboratory, Hayward Genetics Center, Tulane University School of Medicine

References

1. Jamil et al., Cancer Genet Cytogenet 2000;122(2):73-8

2. Borkhardt et al., Blood. 1997 Jul 15;90(2):571-7

3. Mosad et al., Journal of Hematology & Oncology 2008;1:17

4. Raynaud et al., Blood 1996;87(7):2891-9

5. Wang et al., Genes Dev. 1998 Aug 1;12(15):2392-402

Microscope Images

TEL AML1 (ETV6 RUNX1) Translocation Dual Fusion magnified
Area of Interest*
ALL

Disclaimer

This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.

*Disease information supported by the literature and is not a reflection of the intended purpose of this product.